Respiratory biologics layoffs

Quote


GSK has determined that it wants to be a "specialty" company. The problem is that the specialty products they have cannot support a corporation of our current size. Nucala could never stand on its own. There will be a downsizing and rightly so. Probably a 40% cut. Immunology has a few new positions that may offer a few of us refuge but not enough to cover the coming onslaught. You all just saw what happened to our respiratory division...complete blood bath. Those fools are on borrowed time. That division will be gone by 2020.
 
2020 is when the clock strikes midnight. Respiratory division will be gone. Nucala and Benlysta will be one division as will Vaccines and the new Oncology team. Current Nucala division will be cut very soon and Elipta division will be completely gone by 2020. That's the word on the street and the word on Wall Street. Just giving you all the facts. Love em or hate em, they are the facts.
 
anonymous said:
GSK has determined that it wants to be a "specialty" company. The problem is that the specialty products they have cannot support a corporation of our current size. Nucala could never stand on its own. There will be a downsizing and rightly so. Probably a 40% cut. Immunology has a few new positions that may offer a few of us refuge but not enough to cover the coming onslaught. You all just saw what happened to our respiratory division...complete blood bath. Those fools are on borrowed time. That division will be gone by 2020.
Click to expand...


How does Nucala not stand on its own ?
 
Let's look at it this way. You have two reps per territory. Right there you have a half million per year in expenses...salary, bonus, insurance, car retirement etc. How many patient starts do you have per year? And that's being generous because nucala has productions costs, marketing costs, and admin costs. If Nucala were on its own it would be a very small start up company. So small that you wouldn't be driving a free car. You would theoretically be here for the share options that would never pan out. Then factor in the Fesenra and future competition are shrinking your market share. Nucala is only able to succeed do to the strength of the overall GSK portfolio. Don't get me wrong, you contribute but it's a fraction of overall sales.
 
This thread has so much fiction, I don’t know where to start.
*Nucala is the MOST PROFITABLE drug within GSK today.
*Nucala can definitely support its own sales force if it had to.
*there will be an announcement next week that there will be a staff reduction. Approx 30%.
*reps and managers will know there fate by March 30.
*territories will be recut based on smaller indexes than today.
*managers are in the dark until next week.
*may 1 new territories and regions will be in effect.
*reason for 1 person per Terr is that RL wants greater accountability per rep to move business or not.
*yes we are having a National Sales Meeting knowing 30% of RBS’s won’t be here by end of March. Stupid but true.
 
All correct statements with the exception of Nucala being the most profitable. Benlysta did more volume with 1/3 the salesforce and no contracting. Once the reduction happens, then it will become a lot more profitable but how will the price hold up with 2 competitors is unknown.
 
Lots of talk here about things people are “hearing”, does anyone actually know anything concrete? I know many Nucala managers read cafepharma regularly, let’s hear from someone who was actually at the leadership meeting last week. Please no more guessing or trying to interpret what someone may have told someone else who then told you .
 
anonymous said:
Lots of talk here about things people are “hearing”, does anyone actually know anything concrete? I know many Nucala managers read cafepharma regularly, let’s hear from someone who was actually at the leadership meeting last week. Please no more guessing or trying to interpret what someone may have told someone else who then told you .
Click to expand...
I was at the meeting. Both HIV and Respiratory will have sizable cuts in the near future.
 
Some districts/territories have an overlay rep, totally worthless. GSK needs to get rid of that position why would they have this for one product? Reps falling over each other. Stop with letting reps having overnights if they are only 1-2 hours away from home another BS waste of money. Managers need to stop this.

Don’t have a week meeting in March if you have no money. Don’t stay at $250 hotels when staying out on road again ridiculous.
 
FLL here:
I was at the meeting last week and NONE OF THESE THINGS WERE DISCUSSED.
If these rumors are true, someone from above our level knows and leaked them. We will see if they are true or not. FLL’s and Reps are always the last to know.
 


Write your reply...
Top Bottom
Back
Quote